Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

XenoPort Inc.

www.xenoport.com

Latest From XenoPort Inc.

Appointments: EFPIA, Celgene, AcelRx, PureTech Health, Symbiomix, CRISPR Therapeutics and Achaogen

This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.

Appointments

Orphan Drugs Should Be Rarer, Insurers Urge, Citing Price Increases

FDA can improve drug pricing by limiting the number of orphan designations, AHIP argues; worryingly for industry, the agency appears to be already thinking along similar lines.

Legislation Reimbursement

Deals Shaping The Medical Industry, June 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2016.

BioPharmaceutical Medical Device

Deal Watch: Arbor Betting On Building Horizant Commercially As Xenoport Couldn't

Ireland's Jazz pays $1.5bn to acquire Celator and its hotly anticipated leukemia drug, Vyxeos; Spero takes over antibacterial program out-licensed by Vertex; Novartis to copromote Eisai's Lenvima.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Dermatology
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • XenoPort Inc.
  • Senior Management
  • William G Harris, SVP, Fin. & CFO
    Richard K Kim, MD, SVP, Clin. Dev. & Med. Affairs & CMO
  • Contact Info
  • XenoPort Inc.
    Phone: (408) 616-7200
    3410 Central Expressway
    Santa Clara, CA 95051
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register